BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 133 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2018. The put-call ratio across all filers is 0.63 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $423,000 | -82.8% | 10,142 | -81.9% | 0.02% | -84.9% |
| Q2 2019 | $2,458,000 | +56.4% | 56,142 | +83.8% | 0.14% | +47.9% |
| Q1 2019 | $1,572,000 | -2.2% | 30,542 | -28.7% | 0.09% | +28.8% |
| Q3 2018 | $1,608,000 | +33.7% | 42,838 | -8.3% | 0.07% | +52.1% |
| Q1 2018 | $1,203,000 | – | 46,738 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
| Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
| ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
| DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
| Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
| Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |